Results 91 to 100 of about 5,281 (192)

Preventing the Risk of Hospitalization for Respiratory Complications of Influenza among the Elderly: Is There a Better Influenza Vaccination Strategy? A Retrospective Population Study

Vaccines, 2020
Influenza and its complications are an important public health concern, and vaccination remains the most effective prevention measure. However, the efficacy of vaccination depends on several variables, including the type of strategy adopted.
Silvia Cocchio, Tolinda Gallo, Stefania Del Zotto, Elena Clagnan, Andrea Iob, Patrizia Furlan, Marco Fonzo, Chiara Bertoncello, Vincenzo Baldo   +8 more
doaj   +1 more source

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects

, 2009
Background: When H1N1v vaccines become widely available, most elderly subjects will have already received their seasonal influenza vaccination. Adults seeking H1N1v vaccination may be offered seasonal vaccine as well.
GASPARINI, ROBERTO, LATTANZI M, SCHIOPPA F, GAITATZIS N., BARONE M, CASULA D, PELLEGRINI M, VEITCH K, D. Casula, R. Gasparini, M. Barone, N. Gaitatzis, M. Pellegrini, M. Lattanzi, K. Veitch, F. Schioppa   +15 more
core   +2 more sources

MF59-adjuvanted H1N1v vaccine

, 2009
Summary Background:  When H1N1v vaccines become widely available, most elderly subjects will have already received their seasonal influenza vaccination. Adults seeking H1N1v vaccination may be offered seasonal vaccine as well. We investigated prior seasonal vaccination in adult and elderly subjects, and concomitant vaccination with seasonal vaccine in ...
M. Barone, K. Veitch, F. Schioppa, N. Gaitatzis, Michele Pellegrini, Daniela Casula, Maria Lattanzi, Roberto Gasparini   +7 more
openaire   +1 more source

Immunogenicity and safety of MF59-adjuvanted seasonal influenza vaccine and pandemic influenza A (H1N1) vaccine in children : a systematic review

, 2015
Context：Children have very high morbidity and hospitalization rates from seasonal and pandemic influenza. They also play a major role in the spread of influenza disease.
田烨, Tian, Ye
core   +1 more source

Comparison of Ab responses immunized with monovalent and bivalent gp120s formulated in AH and MF59 adjuvants.

, 2018
(A) Ab responses to subtype- matched gp70-V1V2 proteins in MF59 groups. (B) Ab responses to subtype-matched gp70-V1V2 protein in AH groups. (C) Ab responses to strain/subtype-matched gp120s in MF59 groups. (D) Ab responses to matched gp120 to AH groups. (
Susan Zolla-Pazner (156004), Ryan Duffy (779151), Hua-Xin Liao (161409), Susan Hilt (3149133), Christopher Hamlin (5147024), Priyanka Ramesh (1374711), Rushit Lodaya (5147000), DeeAnn Martinez-Guzman (5147021), Ning Li (45258), Xiaoying Shen (164029), Andrea Carfi (203340), Brian Burke (248053), Jerome H. Kim (132312), Nelson L. Michael (132309), William Fulp (459224), Kristian Friedrich (816041), Raphael Gottardo (1558), Hung V. Trinh (5146997), Sai Tian (1795663), Robert J. O’Connell (519953), Christine E. Linton (5147003), Yingxia Wen (2455015), Sayali Onkar (5147009), Barton F. Haynes (140266), Frank Situ (5147006), Giuseppe Palladino (211627), Nathalie Norais (159651), Susan W. Barnett (120170), Mangala Rao (147350), Celia LaBranche (170898), Gillis Otten (5147018), Padma Malyala (5147012), David C. Montefiori (108747), Georgia D. Tomaras (164058), Jeffrey B. Ulmer (120136), Chiara Tani (3572036), Yukti Aggarwal (816042), Yide Sun (334156), Selen Karaca-Griffin (5147015)   +38 more
core   +1 more source

The history of MF59 ^® adjuvant: a phoenix that arose from the ashes

Expert Review of Vaccines, 2013
The first clinical trial of an MF59(®)-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad(®), Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to
Derek T, O'Hagan, Gary S, Ott, Gary Van, Nest, Rino, Rappuoli, Giuseppe Del, Giudice   +4 more
openaire   +2 more sources

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults

Infection & Chemotherapy, 2013
Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere.
openaire   +2 more sources

MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation

Scientific Reports
Abstract Breast cancer is the most common invasive cancer in women worldwide, necessitating innovative therapeutic strategies to enhance treatment efficacy and safety. This study focuses on the development and optimization of novel paclitaxel (PTX)-loaded nanostructured lipid carriers (NLCs) that incorporate components of MF59, an oil-in ...
Marzieh Attar, Fatemeh Tash Shamsabadi, Alireza Soltani, Mohammad Taghi Joghataei, Seyed Reza khandoozi, Shahram Teimourian, Majid Shahbazi, Vahid Erfani-Moghadam   +7 more
openaire   +3 more sources

Anti-gp120 antibody glycoforms in serum of SIV and SHIV studies using MF59, Alum^Alh, or Alum^N adjuvants.

, 2019
Anti-gp120 antibody glycoforms in vaccinated animals: (A) SIV-AlumAlh12.5, n = 27; (B) SIV-MF59, n = 27; (C) AlumN1.9, n = 27; (D) AlumN10.8, n = 8; (E) MF59, n = 8.
Melvin N. Doster (6694943), Ruth M. Ruprecht (8072033), Josh Kramer (1517812), Luca Schifanella (6694940), Celia C. LaBranche (172138), Karin Loré (8072030), Xiaoying Shen (164029), David J. Venzon (7478117), Sanjay Phogat (3780025), Frank Liang (6858878), Hung V. Trinh (5146997), Michelle Metrinko (6858884), Massimiliano Bissa (4811226), David C. Montefiori (7392644), Monica Vaccari (782730), Dallas R. Brown (6694934), Mangala Rao (147350), Galit Alter (91383), Robyn Washington-Parks (8072024), Susan W. Barnett (8072021), Georgia D. Tomaras (7163792), Matthew Breed (6858886), Namal P. M. Liyanage (8072027), Ranajit Pal (782728), William Magnanelli (6858883), Veronica Galli (6858876), Genoveffa Franchini (384425)   +26 more
core   +1 more source

Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine

, 2011
Since initial reports in April 2009, the pandemic influenza A (H1N1) virus has spread globally. Influenza vaccines are the primary method for the control of influenza and its complications.
Hee Jin Cheong, Joon Young Song, Woo Joo Kim, Ji Yun Noh, Won Suk Choi, Dae Won Park, Jung Yeon Heo, Seong-Heon Wie   +7 more
core   +1 more source